Trial · NCT02505971
Nadolol Versus Propranolol in Children With Infantile Hemangiomas
NCT02505971, Phase 3, Completed, The Hospital for Sick Children
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nadolol Versus Propranolol in Children With Infantile Hemangiomas. Trials, record NCT02505971. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02505971
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nadolol Versus Propranolol in Children With Infantile Hemangiomas
- NCT number
- NCT02505971
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 74 participants, actual
- Lead sponsor
- The Hospital for Sick Children
- Conditions
- Infantile Hemangioma
- Interventions
- Nadolol, Propranolol
- First posted
- 2015-07-22
- Last updated
- 2020-10-28
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The change in the bulk (size/extent) and color of the infantile hemangioma (IH)at Week 24 compared to baseline using Visual Analog Scale (VAS). | 24 weeks | A 100 mm visual analog scale (VAS) will be used to quantify changes in the visible bulk (size/extent) and color of the lesion by comparing clinical photographs at 24 weeks versus baseline |
| Secondary | Percent change in IH bulk using VAS at 4, 12, 52 weeks | 4, 12, 52 weeks | A 100 mm visual analog scale (VAS) will be used to quantify changes in the visible bulk (size/extent) of the lesion by comparing clinical photographs at weeks 4, 12, and 52 versus baseline |
| Secondary | Time and dose to reach the 50%, 75% and 100% tumor shrinkage | 52 weeks | Time frame since the baseline and study medication dose, when patient's IH decreased in size by 50%, 75% and 100%. |
| Secondary | Inter-rater reliability of the VAS scores | 52 weeks | Two raters will assess the changes in IH for each study patient ( each visit). We will compare these results to assess inter-rater reliability. |
| Secondary | Percentage of patients achieving functional correction at Week 4, 12, 24, 52 | 4,12,24,52 weeks | Percentage of patients achieving functional correction at Week 4, 12, 24, 52 |
| Secondary | Percent change in the volumetric changes of hemangioma | 24 and 52 weeks | \[(Length + Width)/2\]3 X 0.07 |
| Secondary | Percentage of patients with residual changes (telangiectasias, discoloration, fibro-fatty changes, anetoderma) | 52 weeks | Percentage of patients with residual changes |
| Secondary | Frequency of observed and reported adverse events | 52 weeks | Frequency of observed and reported adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34747977 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02505971
GET https://conductscience.org/api/trials/v1/NCT02505971/registered